Supreme Court won't take up PhRMA-Arkansas 340B expansion case
The US Supreme Court on Monday said it won't hear a case related to the expansion of the federal 340B drug discount program that pitted the industry group PhRMA against the ...
View ArticleTrump elevates disproven vaccines-autism link in interview
In his first major interview since securing another term in the White House, President-elect Donald Trump reiterated concerns with the disproven link between childhood vaccines and autism, a nod to the...
View ArticleRelation and GSK to collaborate on fibrosis, osteoarthritis
Machine learning and AI have sparked a transformation in drug discovery, but cracking the biology is still paramount. That's the thinking behind a new collaboration between UK startup Relation...
View Article#ASH24: Retrospective analysis shows potential for GLP-1s to treat blood clots
SAN DIEGO — As researchers explore more potential benefits of GLP-1 medicines, a new retrospective study is suggesting the drug class’ potential to treat venous thromboembolisms, or blood clots in the...
View Article#ASH24: Kura Oncology details 'aggressive' approach in first-line AML
SAN DIEGO — As Kura Oncology awaits key pivotal data in relapsed or refractory acute myeloid leukemia, the company is going all in on combinations in the frontline setting. On Monday, Kura and its...
View Article#ASH24: Arcellx and Gilead seek to unseat J&J/Legend in multiple myeloma
SAN DIEGO — Gilead and Arcellx say their experimental multiple myeloma cell therapy anito-cel could be a safer rival to field leaders Legend Biotech and Johnson & Johnson. New results from a...
View Article#ASH24: BTK drugs from AstraZeneca, Lilly and BeiGene take center stage in CLL
SAN DIEGO — Some of the biggest names in BTK inhibitors presented updated datasets at the American Society of Hematology annual meeting this weekend, most notably AstraZeneca and Eli Lilly. AstraZeneca...
View ArticleNew oncology biotech launches with $52M in its pocket
A small molecule cancer biotech broke cover on Tuesday with a $52 million Series A to take on a "unique lipidation pocket" and get into the clinic around May of next year. Boston-based Tasca...
View Article#SABCS24: Olema makes case for its oral SERD with fresh data cut from Phase...
Olema Oncology unveiled new data from a Phase 1b/2 breast cancer trial on Tuesday, as it strives to catch up with other companies with oral selective estrogen receptor degraders (SERDs). Olema’s vision...
View ArticleBioNTech reports Phase 1b/2 survival data for VEGF bispecific in breast cancer
Last month, BioNTech went all-in on VEGF bispecific antibodies. On Tuesday, to validate its bet, the company shared early survival data from a mid-stage trial in an aggressive form of breast cancer ...
View ArticleRoche initially didn't want to buy Poseida — and partner Astellas didn't...
Well before Roche said it would buy out its CAR-T partner Poseida Therapeutics for $1 billion upfront, another undisclosed pharma company had sent the cell and gene therapy maker an unsolicited...
View ArticleCervoMed’s Phase 2 miss; NICE to cover Santhera’s Duchenne drug
Plus, news about Lava Therapeutics, Recursion and Aqemia: CervoMed’s dementia drug disappoints in Phase 2: The drugmaker’s neflamapimod missed both the primary and key secondary endpoints in a...
View Article#SABCS24: Early data suggest Arvinas, Pfizer could combine their breast...
Pfizer and its partner Arvinas may have landed on a CDK4/6 inhibitor to use in combination with their oral estrogen receptor degrader in breast cancer. Interim data argue for combining vepdegestrant...
View ArticleHalia Therapeutics takes NLRP3 inhibitor into final stage of Phase 2 trial
Halia Therapeutics is moving its lead asset into the second part of a mid-stage trial following initial positive data in patients with an early form of blood cancer that affects the bone marrow. The...
View ArticleCardiff unveils positive Phase 2 data for colorectal cancer drug, $40M offering
Cardiff Oncology announced an oversubscribed $40 million offering on Tuesday after it released positive data from a mid-stage trial investigating its onvansertib combo in patients with first-line...
View Article#ASH24: J&J, Legend’s Carvykti clears a type of blood cancer in ‘nine out of...
Johnson & Johnson and Legend Biotech say their CAR-T therapy Carvykti has the potential to remove all traces of disease from certain blood cancer patients based on the latest results of a Phase 3...
View ArticleCases of severe RSV in two Moderna vaccine candidates' trials raise questions...
Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children and infants are currently on hold, including two not previously disclosed by...
View ArticleWalgreens in talks to sell to private equity — report
Walgreens is reportedly in discussions to sell itself to a private equity firm as the retail pharmacy giant grapples with store closures and slumping shares. The deal with New York-based private equity...
View ArticleExclusive: Two Vida Ventures co-founders exit the VC firm
Arjun Goyal and Stefan Vitorovic, two of Vida Ventures' three co-founding managing directors, have exited the firm as it rejigs its leadership team seven years after launching. They were both...
View ArticleUniQure stock doubles after FDA meeting on Huntington's disease
Dutch-based uniQure saw its stock {$QURE} rise by more than 120% on Tuesday after it disclosed that it is "in alignment" with the FDA on using the accelerated approval pathway for its experimental...
View Article